Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis

Background: A new goal in treatment of chronic myeloid leukemia (CML) in patients with stable deep molecular response (DMR) is maintaining durable treatment-free remission (TFR) after discontinuing tyrosine kinase inhibitor (TKI) treatment. Methods: We conducted a systematic review and meta-analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Kang-kang, Du, Tai-feng, Xiong, Pei-sheng, Fan, Guan-hua, Yang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527744/
https://www.ncbi.nlm.nih.gov/pubmed/31139566
http://dx.doi.org/10.3389/fonc.2019.00372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527744/
https://www.ncbi.nlm.nih.gov/pubmed/31139566
http://dx.doi.org/10.3389/fonc.2019.00372

Ejemplares similares